A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

NCT04638153

Last updated date
Study Location
DanTrials ApS
Copenhagen NV, , DK-2400, Denmark
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Achondroplasia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-10 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Main cohort: Aged ≥2 years to <11 years (up to the day before 11th birthday inclusive) at time of enrollment; or exploratory cohort: aged ≥3 months to <2 years (up to the day before 2nd birthday inclusive) at time of enrollment

- Documented, confirmed genetic diagnosis of achondroplasia from historical medical records prior to entry into this trial (test must have been performed at a laboratory fully accredited for genetic testing under local regulations).

- Completed the C4181001 natural history study with at least 2 valid height/length measurements (at least 3 months apart) prior to enrollment in this study. One of these measurement timepoints must be within the 3 months prior to enrollment in C4181005.

- Tanner stage 1 based on investigator assessment during physical examination (must include assessment of breast development for females, testicular stage for males).

- Able to stand independently for height measurements (if ≥2 years of age at enrollment).

- If aged <2 years at enrollment, has a documented historical MRI brain/cervical spine performed in the previous 12 months.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Presence of co-morbid conditions or circumstances that, in the opinion of the
investigator, would affect interpretation of growth data or ability to complete the
trial procedures.


- Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.


- Presence of severe obesity (BMI >95th percentile on Hoover-Fong BMI charts)
[Hoover-Fong et al, 2008].14


- Known closure of long bone growth plates (cessation of height growth).


- Body weight <7 kg or >30 kg.


- Severe renal impairment (eGFR <60 mL/min/1.73m2) or hepatic impairment (AST/ALT >1.5
ULN).


- History of hypersensitivity to study intervention or any excipients.


- History of any prior treatment with human growth hormone or related products
(including insulin-like growth factor 1 [IGF-1]).


- History of receipt of any treatment that are known to potentially affect growth
(including oral steroids >5 days in the last 6 months, high dose inhaled
corticosteroids (>800 mcg/day beclametasone equivalent) and medication for attention
deficit hyperactivity disorder).


- History of limb lengthening surgery (defined as distraction
osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to
extend bone length).


- Any limb lengthening/corrective orthopaedic surgery planned at any point during the
trial period.


- Less than 6 months since fracture or surgical procedure of any bone determined from
the screening visit date.


- Presence of any internal guided growth plates/devices.


- History of removal of internal guided growth plates/devices within less than 6 months.


- History of receipt of any investigational product for achondroplasia or that may
affect growth/interpretation of growth parameters.


- History of receipt of an investigational product (not for achondroplasia/growth
affecting) within the last 30 days or 5 half-lives (whichever is longer).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

AchondroplasiaA Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
NCT04638153
  1. Copenhagen NV,
  2. Aliso Viejo, California
  3. Long Beach, California
  4. Torrance, California
  5. Edegem,
  6. Vitoria-Gasteiz, Alava
ALL GENDERS
3 Months+
years
MULTIPLE SITES
AchondroplasiaObservational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
NCT03794609
  1. Izumi, Osaka
  2. Suita, Osaka
  3. Okayama,
  4. Torrance, California
  5. Wilmington, Delaware
  6. Baltimore, Maryland
  7. Boston, Massachusetts
  8. Columbia, Missouri
  9. Cincinnati, Ohio
  10. Houston, Texas
  11. Salt Lake City, Utah
  12. Seattle, Washington
  13. Parkville, Victoria
  14. Antwerp,
  15. Toronto, Ontario
  16. Montreal, Quebec
  17. Kobenhavn,
  18. Marseille,
  19. Paris,
  20. Cologne,
  21. Magdeburg,
  22. San Fermo della Battaglia, Como
  23. Genova, Genoa
  24. Milan,
  25. Rome,
  26. Coimbra,
  27. Barcelona,
  28. Malaga,
  29. Lausanne,
  30. Bristol,
  31. London,
  32. Newcastle upon Tyne,
  33. Sheffield,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
Official Title  ICMJE A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
Brief Summary

Approximately 63 participants will be randomized to one of three doses to receive Recifercept either

  • Low Dose
  • Medium Dose
  • High Dose

Participants will will attend the clinic at baseline and at Day 1, 4, 8, 15, 29 & then Month 2, 3 6, 9 & 12. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements & patient/caregiver quality of life questionnaires

Participants will received treatment with Recifercept for 12 months. All participants who complete the study and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll into an open-label extension (OLE) study.

Detailed Description

This is a phase 2 randomized, 3 arm (3 active doses of Recifercept), parallel group dose finding study of safety, tolerability, PK and efficacy

The total number of participants is 63 in 2 age straified cohorts of 0-2 years and 6-10 years old.

The study will enroll approximately 54 children with achondroplasia aged 2-10 years (inclusive) who will be enrolled and randomized to receive one of three doses of recifercept

  • Low Dose
  • Medium Dose
  • High Dose

A total of 18 participants will be enrolled per dose 18 per dosesuch that at least 15 participants per dose are evaluable. An interim analysis is planned when at least 15 participants per dose aged ?2 to <11 years have received 6 months of treatment with recifercept. eDMC will review safety, PK and efficacy data to confirm ongoing positive benefit:risk in participants.

Additionally, an exploratory cohort of approximately 9 children with achondroplasia, ages 0-2 years, will be enrolled later in the study (n=3 per dose).

Enrollment will follow an age and dose-staggered approach (descending age and ascending dose) with review of safety and PK data by the study team before progression to the next enrollment block If certain pre-defined safety signals occur then a meeting of the eDMC will be convened to make a decision on progression of enrollment. The PK data collected in block A will be used in the PopPK model (developed using healthy adult data) to confirm the dosing for younger children (ie, ?2 to <6 years and 0-<2 years).

Participants will will attend the clinic at baseline and at Day 1, 4, 8, 15, 29 & then Month 2, 3 6, 9 & 12. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements & patient/caregiver quality of life questionnaires

All participants will receive recifercept for 12 months. All participants who complete the study and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll into an open-label extension (OLE) study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
Anthropometric Measurements Assessor
Primary Purpose: Prevention
Condition  ICMJE Achondroplasia
Intervention  ICMJE Biological: Recifercept
Recifercept
Study Arms  ICMJE
  • Experimental: Low Dose
    Low Dose
    Intervention: Biological: Recifercept
  • Experimental: Medium Dose
    Medium Dose
    Intervention: Biological: Recifercept
  • Experimental: High Dose
    High Dose
    Intervention: Biological: Recifercept
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 16, 2020)
63
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 10, 2023
Estimated Primary Completion Date May 10, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Main cohort: Aged ?2 years to <11 years (up to the day before 11th birthday inclusive) at time of enrollment; or exploratory cohort: aged ?3 months to <2 years (up to the day before 2nd birthday inclusive) at time of enrollment
  • Documented, confirmed genetic diagnosis of achondroplasia from historical medical records prior to entry into this trial (test must have been performed at a laboratory fully accredited for genetic testing under local regulations).
  • Completed the C4181001 natural history study with at least 2 valid height/length measurements (at least 3 months apart) prior to enrollment in this study. One of these measurement timepoints must be within the 3 months prior to enrollment in C4181005.
  • Tanner stage 1 based on investigator assessment during physical examination (must include assessment of breast development for females, testicular stage for males).
  • Able to stand independently for height measurements (if ?2 years of age at enrollment).
  • If aged <2 years at enrollment, has a documented historical MRI brain/cervical spine performed in the previous 12 months.

Exclusion Criteria:

  • Presence of co-morbid conditions or circumstances that, in the opinion of the investigator, would affect interpretation of growth data or ability to complete the trial procedures.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Presence of severe obesity (BMI >95th percentile on Hoover-Fong BMI charts) [Hoover-Fong et al, 2008].14
  • Known closure of long bone growth plates (cessation of height growth).
  • Body weight <7 kg or >30 kg.
  • Severe renal impairment (eGFR <60 mL/min/1.73m2) or hepatic impairment (AST/ALT >1.5 ULN).
  • History of hypersensitivity to study intervention or any excipients.
  • History of any prior treatment with human growth hormone or related products (including insulin-like growth factor 1 [IGF-1]).
  • History of receipt of any treatment that are known to potentially affect growth (including oral steroids >5 days in the last 6 months, high dose inhaled corticosteroids (>800 mcg/day beclametasone equivalent) and medication for attention deficit hyperactivity disorder).
  • History of limb lengthening surgery (defined as distraction osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to extend bone length).
  • Any limb lengthening/corrective orthopaedic surgery planned at any point during the trial period.
  • Less than 6 months since fracture or surgical procedure of any bone determined from the screening visit date.
  • Presence of any internal guided growth plates/devices.
  • History of removal of internal guided growth plates/devices within less than 6 months.
  • History of receipt of any investigational product for achondroplasia or that may affect growth/interpretation of growth parameters.
  • History of receipt of an investigational product (not for achondroplasia/growth affecting) within the last 30 days or 5 half-lives (whichever is longer).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 3 Months to 10 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Belgium,   Denmark,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04638153
Other Study ID Numbers  ICMJE C4181005
2020-001189-13 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP